Consensus EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Equities

PV3B

US30233G2093

Market Closed - Deutsche Boerse AG Other stock markets 09:29:01 2024-05-17 am EDT			5-day change	1st Jan Change
11.34 ^EUR	-3.12%		-2.24%	-46.53%

May. 08	Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	MT
May. 08	Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M	MT

Evolution of the average Target Price on EyePoint Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

72e28c.BSX8LwXVrvcWGhuGzNOFjWqhlfIfuoYZaqpzhTihYYA.dW6lTXfgm4VQcCuymuCzzFiYop113_dPMvAb3VTnOeJcCLNccODdoWVvfA~305dcffefc80452077bfcd1a5003c28c

Analyst Recommendations on EyePoint Pharmaceuticals, Inc.

Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating	May. 08	MT
Chardan Research Adjusts EyePoint Pharmaceuticals' PT to $28 From $39 After Data From PAVIA Study of Duravyu Disappoint; Keeps Buy Rating	May. 07	MT
Mizuho Securities Cuts Price Target on EyePoint Pharmaceuticals to $30 From $39, Maintains Buy Rating	May. 07	MT
Mizuho Boosts PT on EyePoint Pharmaceuticals to $39 From $30 Ahead of Q4 2023 Earnings Announcement, Keeps Buy Rating	Feb. 15	MT
JPMorgan Starts EyePoint Pharmaceuticals With Overweight Rating, $35 Price Target	Jan. 22	MT
Capital One Starts Coverage on EyePoint Pharmaceuticals with Overweight Rating, $44 Price Target	Dec. 11	MT
Mizuho Ups Price Target on EyePoint Pharmaceuticals to $30 From $20, Citing 'Resoundingly Positive' Data for Lead Asset EYP-1901, Reiterates Buy Rating	Dec. 07	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $25 From $27, Keeps Buy Rating	Nov. 02	MT
Mizuho Initiates EyePoint Pharmaceuticals With Buy Rating, Price Target is $20	Nov. 02	MT
JonesTrading Initiates EyePoint Pharmaceuticals at Buy With $26 Price Target	23-06-14	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $27 From $25, Keeps Buy Rating	23-05-19	MT
Chardan Raises Price Target on EyePoint Pharmaceuticals to $22 From $21, Keeps Buy Rating	23-05-19	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $52 From $60, Maintains Buy Rating	22-11-11	MT
HC Wainwright Lifts Price Target on EyePoint Pharmaceuticals to $25 From $24, Reiterates Buy Rating	22-08-04	MT
Chardan Capital Initiates EyePoint Pharmaceuticals at Buy with $21 Price Target	22-07-07	MT
Guggenheim Adjusts Price Target on EyePoint Pharmaceuticals to $75 From $22, Maintains Buy Rating	21-11-15	MT
Cowen Adjusts Price Target on EyePoint Pharmaceuticals to $35 From $25, Keeps Outperform Rating	21-11-15	MT
HC Wainwright Adjusts Price Target on EyePoint Pharmaceuticals to $24 From $15, Keeps Buy Rating	21-11-15	MT
EYEPOINT PHARMACEUTICALS : HC Wainwright Adjusts EyePoint Pharmaceuticals' Price Target to $15 From $16, Maintains Buy Rating	21-05-06	MT
EYEPOINT PHARMACEUTICALS : Cowen Starts EyePoint Pharmaceuticals at Outperform with $25 Price Target	21-03-01	MT
EYEPOINT PHARMACEUTICALS : Cantor Fitzgerald Starts EyePoint Pharmaceuticals at Overweight With $22 Price Target	21-01-28	MT
EYEPOINT PHARMACEUTICALS : B. Riley Adjusts EyePoint Pharmaceuticals' Price Target to $8.50 from $5, Keeps Neutral Rating	21-01-12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.84 USD

Average target price

39.11 USD

Spread / Average Target

+230.33%

High Price Target

68 USD

Spread / Highest target

+474.32%

Low Price Target

28 USD

Spread / Lowest Target

+136.49%

Consensus detail

Consensus revision (last 18 months)

Analysts covering EyePoint Pharmaceuticals, Inc.

Baird
Chardan Research
Mizuho Securities
JPMorgan Chase
Capital One Securities
HC Wainwright
JonesTrading Institutional Services
Guggenheim
Cowen
Cantor Fitzgerald
B. Riley

Ratings for EyePoint Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar